{"id":48007,"date":"2022-09-06T15:02:03","date_gmt":"2022-09-06T13:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/"},"modified":"2022-09-06T15:02:03","modified_gmt":"2022-09-06T13:02:03","slug":"pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/","title":{"rendered":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation"},"content":{"rendered":"
\n

BELLEVUE, Wash.–(BUSINESS WIRE)–#CurvaFixImplant<\/a>—CurvaFix, Inc<\/a>., a developer of medical devices to repair fractures in curved bones, today announced the completion of the 100th<\/sup> surgical procedure using the CurvaFix\u00ae IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo. The surgery was performed by orthopedic trauma surgeon Brett D. Crist, M.D., Director of the Orthopaedic Trauma Service and Orthopaedic Trauma Fellowship.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe 70-year-old geriatric female patient with osteoporosis sustained a low-energy fall almost seven months ago. She was referred to Dr. Crist for the CurvaFix Implant procedure after experiencing limited mobility and continued pain following nonoperative management, including osteoporosis treatment. According to Dr. Crist, \u201cThe patient tolerated the minimally invasive procedure very well. The CurvaFix Implant was easily steered around existing lumbosacral fusion hardware from a previous surgery, for ideal implant placement conforming to the patient\u2019s individual bone shape within the remaining first sacral segment corridor, to the opposite ilium, and provided strong, stable fixation in poor-quality bone.\u201d\n<\/p>\n

\nThe CurvaFix IM Implant<\/a> procedure can simplify pelvic fracture fixation by enabling surgeons to choose an optimal entry point, allowing them to steer within the bone to follow each patient\u2019s bone shape and fill the bone corridor resulting in strong, curved fixation with a minimally invasive procedure. For patients with fragility fractures of the pelvis (FFP), strong, curved fixation in weak bone with the CurvaFix Implant may immediately reduce pain, enable earlier mobility, and improve patient recovery compared to traditional methods.\n<\/p>\n

\n\u201cThe 100th<\/sup> patient treated by the CurvaFix Implant is an important milestone for CurvaFix and is indicative of a large unmet clinical need our curved implant can address in patients suffering from fragility or high-impact fractures of the pelvis,\u201d said Steve Dimmer, chief executive officer for CurvaFix. \u201cIt is our commitment to offer surgeons and their patients strong, curved fracture fixation throughout the pelvis in a minimally invasive, easy procedure with potential for immediate pain relief, earlier mobility, and faster recovery. This is especially important for fragility fracture patients where mobility is key to life.\u201d\n<\/p>\n

\nOver 186,000 hospitalizations occur due to pelvic fractures yearly in the U.S and an estimated 70,000 pelvic fracture surgeries in the U.S. The incidence of fragility fractures of the pelvis (FFP) is an increasing health problem in America\u2019s aging society, affecting over 108,000 of these patients.1<\/sup> Pelvic fragility fractures can dramatically change the quality of life for patients and their families due to a loss of patient autonomy, significant disability, and even death.\n<\/p>\n

\nDespite recommendations that surgical treatment should be considered for most fragility fractures of the pelvis, only 10% receive surgery today. For non-operative patients, conservative treatment generally consists of bed confinement, pain control, and mobility assistance while tolerating weight-bearing. Often, conservative treatment leads to lengthy hospitalizations, high nursing home admittance, and a high one-year mortality rate.\n<\/p>\n

\nAbout CurvaFix, Inc.<\/b>\n<\/p>\n

\nCurvaFix, Inc.<\/a> is a privately held medical device company headquartered in Bellevue, Wash. CurvaFix is developing implantable products to improve fracture repair in curved bones. The company is focusing on Fragility Fractures of the Pelvis (FFP) and high-impact pelvic fractures. The CurvaFix IM Implant has received 510(k) clearance from the U.S. FDA.\n<\/p>\n

\nCurvaFix is a trademark of CurvaFix, Inc., registered in the U.S.\n<\/p>\n

\n_________________________\n<\/p>\n

\n1<\/sup> 2022 Trauma Update, Orthopedic Network News, Volume 33, No. 2, May 2022.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAmy Cook
\n
Acook@curvafix.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BELLEVUE, Wash.–(BUSINESS WIRE)–#CurvaFixImplant—CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the completion of the 100th surgical procedure using the CurvaFix\u00ae IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo. The surgery was performed by … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48007","6":"format-standard","7":"category-industry"},"yoast_head":"\nPelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BELLEVUE, Wash.–(BUSINESS WIRE)–#CurvaFixImplant—CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the completion of the 100th surgical procedure using the CurvaFix\u00ae IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo. The surgery was performed by ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T13:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation\",\"datePublished\":\"2022-09-06T13:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/\"},\"wordCount\":585,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005088\\\/en\\\/1560072\\\/21\\\/2_Standalone_Main_Photo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/\",\"name\":\"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005088\\\/en\\\/1560072\\\/21\\\/2_Standalone_Main_Photo.jpg\",\"datePublished\":\"2022-09-06T13:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005088\\\/en\\\/1560072\\\/21\\\/2_Standalone_Main_Photo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005088\\\/en\\\/1560072\\\/21\\\/2_Standalone_Main_Photo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/","og_locale":"en_US","og_type":"article","og_title":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend","og_description":"BELLEVUE, Wash.–(BUSINESS WIRE)–#CurvaFixImplant—CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the completion of the 100th surgical procedure using the CurvaFix\u00ae IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo. The surgery was performed by ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-06T13:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation","datePublished":"2022-09-06T13:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/"},"wordCount":585,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/","url":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/","name":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg","datePublished":"2022-09-06T13:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220906005088\/en\/1560072\/21\/2_Standalone_Main_Photo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pelvic-fragility-fracture-patient-at-the-university-of-missouri-in-columbia-is-the-100th-person-treated-with-curvafix-im-implant-for-pelvic-fracture-fixation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Pelvic Fragility Fracture Patient at the University of Missouri in Columbia is the 100th Person Treated with CurvaFix IM Implant for Pelvic Fracture Fixation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48007"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48007\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}